Boston-based Haemonetics will retain all intellectual property rights to its proprietary blood filters currently manufactured at its Fajardo facility, while GVS (Bologna, Italy) will obtain certain operating assets, including manufacturing equipment and inventory and a sublease to the facility.
Haemonetics also plans to grant GVS exclusive rights to manufacture and supply the blood filters currently produced at the Fajardo facility. Haemonetics employees who work in the Fajardo facility will become GVS employees.
The deal is expected to close in the second quarter of 2020. It’s the second recent transaction for the blood management company, which announced May 29 that it plans to sell certain blood donor management software assets to the GPI Group.
“We continue to pursue operational excellence to offer our customers high quality products through an asset-lite approach,” said Haemonetics president & CEO Chris Simon in a news release. “We are confident that GVS’ experience and scale in filtration will help us deliver reliable, cost-efficient products.”
“We are honored that Haemonetics, an industry leader and one of our long-term clients, has chosen GVS for this strategic partnership, which is testament to our technological and process capabilities,” added GVS CEO Massimo Scagliarini. “This collaboration will provide us with a new channel for R&D, stimulating the introduction of new products, ideas and solutions for the blood filtration market.”